Investing.com - Avadel Pharma reported on Tuesday second quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Avadel Pharma announced earnings per share of $-1.07 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.4225 on revenue of $0.00.
Avadel Pharma shares are down 13.99% from the beginning of the year and are trading at $6.950 , down-from-52-week-high.They are outperforming the Nasdaq which is down 20.22% from the start of the year.
Avadel Pharma shares gained 10.14% in intra-day trade the report.
Avadel Pharma follows other major Healthcare sector earnings this month
Avadel Pharma's report follows an earnings beat by UnitedHealth on July 15, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on July 19 with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.54 on revenue of $23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar